Skip to content
Welcure Drugs & Pharmaceuticals logo

Welcure Drugs & Pharmaceuticals

524661 BSE
Price unavailable

Welcure Drugs & Pharmaceuticals (WELCURE) share price was ₹0.19 at the 28 Oct 2026 close; market capitalisation ₹23.50 Cr; sector Healthcare. The share price fell 69.4% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Mar 2026 quarter, revenue fell 100.0% year on year to under ₹0.1 Cr and net profit was −₹50 Cr, against ₹3 Cr a year earlier (compared with Mar 2025). Promoters held 0.00% of Welcure Drugs & Pharmaceuticals in Mar 2026, unchanged from Dec 2025. Its Tapetide Score is 56/100 (Good) as of 28 Oct 2026.

Close 28 Oct 2026 ₹0.19 −0.40 −67.80% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹23.50 Cr
EBITDA
−₹6.93 Cr
Return on Equity
2.12%
Debt to Equity
0
Book Value
₹0.79
EPS (TTM)
−₹0.13
52W High
₹0.64
52W Low
₹0.17

Price-based figures as of 28 Oct 2026, 15:30 IST · EPS basis: Standalone · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,766.5035.044,23,843 Cr5.070.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,631.0087.412,55,673 Cr15.250.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,596.5072.161,74,836 Cr9.520.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,183.50107.881,17,977 Cr22.260.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,180.9026.281,17,795 Cr4.350.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,340.8034.731,11,914 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,370.8032.841,10,741 Cr3.130.96%11.21%14.88%28,589 Cr3,356 Cr
Welcure Drugs & Pharmaceuticals (this company)
——24 Cr0.240.00%2.12%1.23%367 Cr-18 Cr
Median 8 companies₹1,766.5035.041,17,886 Cr4.710.47%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

56 Good
Overall score

Data confidence 88/100

Category scores

Quality Good 55
Returns, margins, earnings quality 22% weight
Valuation Strong 72
Cheap vs sector & own history 24% weight
Growth Strong 99
Sales & profit trajectory 9% weight
Financial Health Weak 44
Solvency, leverage, coverage 9% weight
Momentum Poor 11
Trend strength, vol-adjusted 12% weight
Ownership Average 50
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company has reduced debt.
  • Company is almost debt free.
  • Stock is trading at 0.25 times its book value

Weaknesses

3
  • Company has low interest coverage ratio.
  • Company has a low return on equity of -2.28% over last 3 years.
  • Company has high debtors of 213 days.

Technical Indicators

Oscillators

Bearish

Bearish
3
Neutral
5
Bullish
1

Overall

Bearish

Bearish
13
Neutral
5
Bullish
1

Moving Averages

Bearish

Bearish
10
Neutral
0
Bullish
0

Growth Rate

Revenue Growth
—

Net Income Growth
-350%

change over 1 year

EBITDA Margin Change
-118%

change over 1 year

Quarterly Results

Particulars Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales
0
0
0
0
0
0
25
1
21
300
66
0
0
Expenses
0
0
0
0
0
0
23
1
21
269
54
0
50
Operating Profit
0
0
0
0
0
0
2
0
1
31
11
0
-50
OPM %
—
—
—
—
—
—
7%
10%
3%
10%
17%
—
—
Other Income
0
0
0
0
0
0
0
0
2
0
0
1
0
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
0
PBT
0
0
0
0
0
0
2
0
3
31
11
1
-50
Tax %
0%
0%
0%
0%
0%
0%
0%
56%
0%
25%
25%
25%
0%
Net Profit
0
0
0
0
0
0
2
0
3
23
8
1
-50
EPS (₹)
0.01
0
-0.01
0
0
-0.02
0.01
0
0.02
0.19
0.07
0.01
-0.4
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
0
0
0
0
0
0
0
0
0
0
25
366
Expenses
0
0
0
0
0
0
0
0
0
0
24
372
Operating Profit
0
0
0
0
0
0
0
0
0
0
1
-7
OPM %
20%
40%
33%
-40%
0%
-12%
46%
18%
—
—
4%
-1.9%
Other Income
0
0
0
0
0
0
0
0
0
0
2
1
Interest
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
PBT
0
0
0
0
0
0
0
0
0
0
3
-5
Tax %
0%
0%
0%
0%
—
0%
0%
0%
0%
0%
22%
0%
Net Profit
0
0
0
0
0
0
0
0
0
0
2
-5
EPS (₹)
0
0.01
0
0
0
0
0
0
0.01
-0.01
0.02
-0.04
Div. Payout %
0%
0%
0%
0%
—
0%
0%
0%
0%
0%
0%
0%
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
12
12
12
12
12
12
12
12
13
13
112
124
Reserves
-12
-12
-12
-12
-12
-12
-12
-12
-12
-12
-10
-27
Borrowings
0
0
0
0
0
0
0
0
0
0
123
0
Other Liabilities
0
0
0
0
0
0
0
0
0
0
41
413
Total Liabilities
0
0
0
0
0
0
0
0
2
1
267
510
Fixed Assets
0
0
0
0
0
0
0
0
0
0
0
0
CWIP
0
0
0
0
0
0
0
0
0
0
0
0
Investments
0
0
0
0
0
0
0
0
0
0
0
1
Other Assets
0
0
0
0
0
0
0
0
1
1
267
509
Total Assets
0
0
0
0
0
0
0
0
2
1
267
510
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0
0
0
0
0
0
0
0
0
0
-222
2
Investing
0
0
0
0
0
0
0
0
0
0
0
-1
Financing
0
0
0
0
0
0
0
0
0
0
222
0
Net Cash Flow
0
0
0
0
0
0
0
0
0
0
0
0
Free Cash Flow
0
0
0
0
0
0
0
0
0
0
-222
2
CFO/OP
100
-125
67
50
—
100
67
100
-79
57
-22,890
-25
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
—
—
—
—
—
—
—
—
—
—
282
213
Inventory Days
—
—
—
—
—
—
—
—
—
—
2,554
162
Days Payable
—
—
—
—
—
—
—
—
—
—
52
226
Cash Conversion Cycle
—
—
—
—
—
—
—
—
—
—
2,784
150
Working Capital Days
—
—
—
—
—
—
—
—
—
—
2,092
-56
ROCE %
—
—
120%
-67%
0%
-40%
133%
25%
10%
-13%
3%
-3%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Welcure Drugs & Pharmaceuticals insights

63 extracted metrics + investor summaries across FY10–FY26.

Shareholding Pattern

Public95.63%Others4.37%As ofMar 2026

Documents

Frequently Asked Questions about Welcure Drugs & Pharmaceuticals

What does Welcure Drugs & Pharmaceuticals Ltd do?
Incorporated in 1992, Welcure Drugs and Pharmaceuticals Ltd is in the business of pharmaceutical and healthcare.[1]
Where is Welcure Drugs & Pharmaceuticals Ltd (WELCURE) listed?
Welcure Drugs & Pharmaceuticals Ltd trades under code 524661 on the BSE.
Which sector does Welcure Drugs & Pharmaceuticals Ltd belong to?
Welcure Drugs & Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Welcure Drugs & Pharmaceuticals Ltd?
Welcure Drugs & Pharmaceuticals Ltd has a market capitalisation of ₹23.5 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the 52-week high and low of Welcure Drugs & Pharmaceuticals Ltd?
Over the last 52 weeks Welcure Drugs & Pharmaceuticals Ltd has traded between ₹0.17 and ₹0.64 as of 28 Oct 2026.
What is the Return on Equity (ROE) of Welcure Drugs & Pharmaceuticals Ltd?
Welcure Drugs & Pharmaceuticals Ltd reported a return on equity of 2.12%. Its debt-to-equity ratio is 0.00.

Company Information

Incorporated in 1992, Welcure Drugs and Pharmaceuticals Ltd is in the business of pharmaceutical and healthcare.[1]

Face Value ₹ 1
Shares Outstanding 1,23,68,42,105

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524661.md for Welcure Drugs & Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month